Paxman Scalp Cooling, the global expert in preventing chemotherapy-induced alopecia, continues to address this unmet need in side effect management, and strives to improve access to the treatment for patients across the US and internationally.
FDA cleared, the Paxman cold cap is proven to be efficacious, tolerable and safe by multiple robust studies conducted all over the world. The treatment is clinically proven to encourage faster hair regrowth, even with significant hair loss.
National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in oncology for breast cancer (Version 1.2019) and ovarian cancer, fallopian tube cancer and primary peritoneal cancer (Version 1.2020) include scalp cooling as a Category 2A recommendation.
The Scalp Cooling Study Library unites key clinical research studies and data to provide an independent overview of global research and practice on scalp cooling and cryotherapy for chemotherapy side effect management.